Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors
- PMID: 12593661
- DOI: 10.1021/jm020377a
Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors
Abstract
A series of sulfonamide hydroxamic acids and anilides have been synthesized and studied as histone deacetylase (HDAC) inhibitors that can induce hyperacetylation of histones in human cancer cells. The inhibition of HDAC activity represents a novel approach for intervening in cell cycle regulation. The lead candidates were screened in a panel of human tumor and normal cell lines. They selectively inhibit proliferation, cause cell cycle blocks, and induce apoptosis in human cancer cells but not in normal cells. The structure-activity relationships, the antiproliferative activity, and the in vivo efficacy are described.
Similar articles
-
Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors.Cancer Res. 2002 Aug 1;62(15):4325-30. Cancer Res. 2002. PMID: 12154036
-
2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.J Med Chem. 2007 Sep 6;50(18):4405-18. doi: 10.1021/jm0703136. Epub 2007 Aug 11. J Med Chem. 2007. PMID: 17691763
-
Design, synthesis and preliminary biological evaluation of new hydroxamate histone deacetylase inhibitors as potential antileukemic agents.Bioorg Med Chem Lett. 2008 Sep 15;18(18):5071-4. doi: 10.1016/j.bmcl.2008.07.119. Epub 2008 Aug 3. Bioorg Med Chem Lett. 2008. PMID: 18723349
-
Novel hydroxamate and anilide derivatives as potent histone deacetylase inhibitors: synthesis and antiproliferative evaluation.Curr Med Chem. 2003 Nov;10(22):2359-72. doi: 10.2174/0929867033456585. Curr Med Chem. 2003. PMID: 14529479 Review.
-
Histone deacetylase inhibitors: the Abbott experience.Curr Med Chem. 2003 Nov;10(22):2373-92. doi: 10.2174/0929867033456576. Curr Med Chem. 2003. PMID: 14529480 Review.
Cited by
-
SelSA-1, a novel HDAC inhibitor demonstrates enhanced chemotherapeutic potential by redox modulation.Sci Rep. 2023 Jun 8;13(1):9301. doi: 10.1038/s41598-023-36555-w. Sci Rep. 2023. PMID: 37291249 Free PMC article.
-
Pharmacokinetics-pharmacodynamics and antitumor activity of mercaptoacetamide-based histone deacetylase inhibitors.Mol Cancer Ther. 2009 Oct;8(10):2844-51. doi: 10.1158/1535-7163.MCT-09-0629. Epub 2009 Sep 29. Mol Cancer Ther. 2009. PMID: 19789216 Free PMC article.
-
Exploration of Novel Inhibitors for Class I Histone Deacetylase Isoforms by QSAR Modeling and Molecular Dynamics Simulation Assays.PLoS One. 2015 Oct 2;10(10):e0139588. doi: 10.1371/journal.pone.0139588. eCollection 2015. PLoS One. 2015. PMID: 26431201 Free PMC article.
-
An adamantyl-substituted retinoid-derived molecule that inhibits cancer cell growth and angiogenesis by inducing apoptosis and binds to small heterodimer partner nuclear receptor: effects of modifying its carboxylate group on apoptosis, proliferation, and protein-tyrosine phosphatase activity.J Med Chem. 2007 May 31;50(11):2622-39. doi: 10.1021/jm0613323. Epub 2007 May 10. J Med Chem. 2007. PMID: 17489579 Free PMC article.
-
Methods for Hydroxamic Acid Synthesis.Curr Org Chem. 2019;23(9):978-993. doi: 10.2174/1385272823666190424142821. Curr Org Chem. 2019. PMID: 32565717 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information